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A screen for modulators of autophagy in
Vici Syndrome iPS cells

Intro
Vici Syndrome (VS) is a devastating genetic pediatric disorder with complex
clinical phenotypes. Affected children exhibit profound developmental delay,
seizures, hypotonia, immunodeficiency, cardiomyopathy, and progressive loss of
motor function, with a median survival of 42 months. This recessive genetic
disorder is caused by deleterious variants in the EPG5 locus. This gene encodes a
critical component of the intracellular machinery which couples autophagocytic
material to the lysosome for degradation. In the absence of EPG5 function,
autophagy is impaired, resulting in selective and progressive neuronal and other
cellular damage leading to the complex phenotypes of Vici Syndrome. VS is thus
a member of an expanding class of diseases, termed congenital disorders of
autophagy, in which deficits in autophagy are believed to be the underlying
driver of the disease. There are essentially no treatment options for children
with Vici Syndrome.
Therapies are desperately needed to enhance and extend the quality of life of
these children. The overarching long term goals of this project are to identify
small molecules that enhance autophagy for use in treatment of this devastating
disorder, in a precision therapeutic effort.

Engineering of pathogenic
EPG5 variants in mouse
model using CRISPR

Summary of screen. Cells are plated in a 96 or 384 well multiwell plate and treated with small molecules for 48 hours. A two-step analysis of the
cells is performed to quantify cell number and to assess the autophagy reporter activity. Initial hits are further analyzed via secondary assays.
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Establishment of primary fibroblasts from Epg5 mutant
mice for future biochemical and cellular analyses

Rapalogs substantially reduce reporter activity, indicating
enhancement of autophagy, in undifferentiated Vici Syndrome
iPS cells.

A screen for modulators of autophagy in neurally differentiated iPS cells. VS iPS cells were
directed to differentiate to a mixed spinal interneuron progenitor phenotype and treated with
known modulators of autophagy (Enzo Pharmaceuticals). Several compounds, include several FDA
approved drugs, are seen to enhance autophagy in this primary screen.
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Analysis of differentiated cells from
Vici Syndrome iPS cells

Conclusions and Future Directions

Autophagy reporter activity in differentiated cells

Targeting of autophagy reporter
transgene in iPS cells via CRISPR
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Vici Syndrome patient specific iPS cell
lines were generated from skin biopsies

•

A targeting strategy was employed to
integrate a novel reporter for autophagy

•

•

Multiple cell-based drug screens have
identified putative enhancers of
autophagy in VS-derived cells

•

•

Two mouse models have recently been
generated via CRISPR genome editing
that recapitulate pathological EPG5
variants in VS patients
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Modeling Vici Syndrome in Cells
When the autophagosome fuses with the lysosome, LC3 is degraded, resulting in the loss of
the genetically engineered luciferase signal. Fusion of the autophagosome with the lysosome
is mediated by the EPG5 protein.

sibling

Clinical Phenotype

EPG5 Genotype

GM27291

Less severe

Q336R / Q336R

normalized activity

Cell Line

100

50

0

GM27898
GM27895

More severe
Sibling control

W865X / L1067Yfs*10
WT / WT

no treatment

cell line

normalized reporter activity

mild
severe

Summary of cell lines from Vici Syndrome patients

neuron

autophagy reporter
Vici Syndsrome
undifferentiated iPS cells

autophagy reporter activity
150

400

-

Baf

cardiomyocyte

-

Baf

neuron

phenotype

Pulse Plot Analysis of Beating Cardiomyocytes
Sibling control cells
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A novel reporter of autophagy
in pluripotent stem cells
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Genetically engineered mouse models of Vici Syndrome

•

Secondary reporter screens and orthogonal
assays of autophagy will be used to
characterize the initial small molecule hits
The Epg5 mutant mouse strains will be
characterized for phenotypes to assess
disease onset and severity
Drug candidates will be tested in the mouse
models
Immunofluorescence imaging
of autophagocytic vesicles in
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Vici Syndrome patient-derived iPS cells lines were engineered to carry a novel reporter of
autophagy using CRISPR mediated gene targeting. The severe VS-derived iPS cell line shows
significantly higher activity, indicative of reduced autophagocytic activity. This reporter is
highly responsive to known modulators of autophagy.

Patient fibroblasts can be reprogrammed to become induced pluripotent stem cells (iPSCs), which
are then modified with CRISPR/Cas9 to add the luciferase tag at LC3 as an autophagy marker.
Multiple differentiated cell types can be derived from iPSCs.

Pulse Video Analysis software
(Maddah et al., 2015) was used to
measure beating rates of
cardiomyocytes in culture. We can
use this software to quantitatively
analyze contraction differences
between our Vici Syndrome cell
lines and the sibling control.
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